SAN DIEGO, Oct. 30, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX) announced today that its third quarter 2017 financial results will be released on Thursday, November 9, 2017, after the market close. At 4:30 pm Eastern Time, Pfenex management will host a conference call to discuss the financial results and provide a business update. A press release outlining the financial results and business update will be publicly distributed prior to the call.
Please call 1-866-376-8058 (US) or 1-412-317-6011 (international) and reference Pfenex to access the call. A replay of the conference call will be available approximately one hour after the call until November 16, 2017. To access the teleconference replay please call 1-877-344-7529 (US) or 1-412-317-0088 (international) and enter the passcode 10113809. The conference call will also be available as a webcast. To access the webcast link please log on to www.pfenex.com.
Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The company's lead product candidates are PF708, a therapeutic equivalent candidate to Forteo® (teriparatide) for the treatment of osteoporosis, and PF582, a biosimilar candidate to Lucentis® (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfēnex Expression Technology® platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, therapeutic equivalents to reference listed drug products, and next generation biologics.